Exchange Traded Concepts LLC Buys 7,924 Shares of Cencora, Inc. $COR

Exchange Traded Concepts LLC grew its position in Cencora, Inc. (NYSE:COR) by 312.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,458 shares of the company’s stock after buying an additional 7,924 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Cencora were worth $3,268,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of COR. Vanguard Group Inc. raised its stake in Cencora by 5.3% in the second quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock worth $6,740,340,000 after buying an additional 1,125,661 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Cencora by 6.3% in the 2nd quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock valued at $1,429,772,000 after acquiring an additional 284,229 shares during the period. Norges Bank bought a new position in shares of Cencora in the 2nd quarter worth $695,215,000. Viking Global Investors LP lifted its stake in shares of Cencora by 95.0% during the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after purchasing an additional 1,013,913 shares during the last quarter. Finally, Amundi boosted its position in Cencora by 17.0% during the second quarter. Amundi now owns 1,720,278 shares of the company’s stock valued at $500,893,000 after purchasing an additional 249,742 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Cencora Price Performance

Shares of NYSE:COR opened at $343.17 on Friday. Cencora, Inc. has a twelve month low of $223.92 and a twelve month high of $377.54. The company’s 50 day moving average is $348.33 and its 200 day moving average is $314.46. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. The company has a market cap of $66.57 billion, a PE ratio of 43.17, a price-to-earnings-growth ratio of 1.62 and a beta of 0.63.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating the consensus estimate of $3.79 by $0.05. The business had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the business posted $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, sell-side analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, November 14th. This represents a $2.40 annualized dividend and a yield of 0.7%. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is 30.19%.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,677 shares of Cencora stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the transaction, the executive vice president owned 18,796 shares in the company, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the sale, the chief executive officer owned 37,940 shares in the company, valued at $12,398,792. The trade was a 11.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 20,317 shares of company stock worth $7,009,260. Insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on COR shares. JPMorgan Chase & Co. boosted their target price on shares of Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Wall Street Zen lowered shares of Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. Evercore ISI set a $400.00 target price on shares of Cencora and gave the company an “outperform” rating in a research report on Thursday, November 6th. Wells Fargo & Company lifted their price target on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Cencora in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $373.25.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.